Multiple Myeloma: all 3,712 studies
Page 23 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled TrialCompletedNCT04099901Phase 2
- A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantActive, not recruitingNCT04096066Phase 3
- Ixazomib + Pomalidomide + Dexamethasone In MMActive, not recruitingNCT04094961Phase 1/2
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)CompletedNCT04093596Phase 1
- Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04091126Phase 1
- Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary CaregiversActive, not recruitingNCT04090619
- Isatuximab, Bendamustine, and Prednisone in Refractory Multiple MyelomaTerminatedNCT04083898Phase 1
- First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)CompletedNCT04083534Phase 1/2
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
- Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM PatientsCompletedNCT04065789Phase 2
- Daratumumab With DCEP for Multiple Myeloma With PlasmacytomaStatus unknownNCT04065308Phase 2
- Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple MyelomaStatus unknownNCT04063189Phase 2
- Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMMCompletedNCT04052880Phase 2
- Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04045795Phase 1
- Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy PrimocureCompletedNCT04045561
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological DiseaseCompletedNCT04039100Not applicable
- A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT04036461Phase 1
- A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody TreatmentCompletedNCT04035226
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
- Bone Healing During Ninlaro ExposureCompletedNCT04028115Phase 2
- A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced CancersTerminatedNCT04025216Phase 1
- Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From HLA-identical or Haploidentical Family Donor in the Treatment of Refractory or Relapsed Multiple Myeloma: a Phase 2 TrialWithdrawnNCT04024384Phase 2
- A Study of MT-0169 in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT04017130Phase 1
- Collect and Assess Tissue Samples From Subjects With Hematologic MalignancyCompletedNCT04014764
- Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMActive, not recruitingNCT04009109Phase 2
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma PatientsStatus unknownNCT04008888Not applicable
- Carfilzomib in Combination for the Treatment of RR MMStatus unknownNCT04004338
- Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple MyelomaStatus unknownNCT04003168Phase 1
- First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple MyelomaCompletedNCT04000282Phase 1
- A Clinical Research of CD22-Targeted CAR-T in B Cell MalignanciesStatus unknownNCT03999697Phase 1
- A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCompletedNCT03997968Phase 1/2
- Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose TherapyCompletedNCT03993912Phase 3
- Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positiveStatus unknownNCT03992170Phase 2
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingNCT03989414Phase 1/2
- A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)CompletedNCT03984097Phase 1
- Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple MyelomaWithdrawnNCT03983486
- Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCTStatus unknownNCT03977103Phase 2
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Active, not recruitingNCT03975907Phase 1/2
- Effect of Vitamin C in Autologous Stem Cell TransplantationsCompletedNCT03964688Phase 2
- Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCTTerminatedNCT03963024Phase 1
- In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant PatientsCompletedNCT03960619Not applicable
- A Study to Desensitize Allergic Reactions to Treatments for Blood DisordersCompletedNCT03959358Phase 2
- A Registry Study of Participants With Multiple Myeloma in Latin AmericaCompletedNCT03955900
- Leflunomide in Treating Patients With High-Risk Smoldering Multiple MyelomaWithdrawnNCT03952832Phase 2
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Phase 3
- Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMActive, not recruitingNCT03948035Phase 3
- Physical Activity for Myeloma Autograft Longitudinal StudyTerminatedNCT03946332Not applicable
- BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple MyelomaStatus unknownNCT03943472Early Phase 1
- Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT03942224Phase 2
- Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MMStatus unknownNCT03940833Phase 1/2
- A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03933735Phase 1/2
- B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple MyelomaStatus unknownNCT03931421Phase 2
- Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)Active, not recruitingNCT03915184Phase 1/2
- RDD Versus VDD in Newly Diagnosed Patients With Multiple MyelomaStatus unknownNCT03908138Phase 4
- Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot StudyStatus unknownNCT03903406
- Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-DaraActive, not recruitingNCT03896737Phase 2
- Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple MyelomaCompletedNCT03891914Phase 3
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple MyelomaCompletedNCT03870633
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Phase 2
- Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
- Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple MyelomaNo longer availableNCT03850704
- PD-L1 Peptide Vaccination in High Risk Smoldering Multiple MyelomaTerminatedNCT03850522Phase 2
- Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple MyelomaCompletedNCT03848676
- An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical TrialActive, not recruitingNCT03844048Phase 3
- Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaWithdrawnNCT03841565Phase 2
- Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaActive, not recruitingNCT03836014Phase 3
- STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAActive, not recruitingNCT03829371Phase 4
- Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03829020Phase 1
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03815383Phase 1
- Study to Demonstrate Clinical Benefit of Lenalidomide and DexamethasoneActive, not recruitingNCT03809780Phase 2
- 64Cu-LLP2A for Imaging Multiple MyelomaTerminatedNCT03804424Early Phase 1
- CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT03798678Phase 1
- Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Status unknownNCT03795597Phase 1/2
- Strength Training in Improving Pain and Quality of Life in Patients With Multiple MyelomaCompletedNCT03793907Not applicable
- Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma PatientsCompletedNCT03792763Phase 2
- Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara ConsolidationStatus unknownNCT03792620Phase 3
- A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose TherapyWithdrawnNCT03785184Phase 2
- Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission TomographyCompletedNCT03779815Not applicable
- Lenalidomide Adherence in Older AdultsTerminatedNCT03779555
- Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple MyelomaTerminatedNCT03777410
- The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple MyelomaCompletedNCT03777306Not applicable
- Vascular Functions in Myeloma Patients During Anti-tumor TherapyStatus unknownNCT03776331
- A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory AgentCompletedNCT03768960Phase 4
- A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT03767751Phase 1/2
- Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple MyelomaStatus unknownNCT03767725Phase 1
- Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT03763162Phase 2
- Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin VaccineCompletedNCT03762291Phase 1
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Phase 2
- Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaTerminatedNCT03757221Phase 2
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- Efficacy and Safety Evaluation of BCMA-UCARTSuspendedNCT03752541Not applicable
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03751293Phase 1
- Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT03746652Phase 2
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101Active, not recruitingNCT03741127Phase 1
- Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03733717Phase 1
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2